Shire PLC (SHP) Stock Rating Reaffirmed by Deutsche Bank AG
Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by Deutsche Bank AG in a research note issued to investors on Thursday. They presently have a GBX 5,700 ($75.61) price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s price objective would suggest a potential upside of 46.98% from the stock’s previous close.
SHP has been the topic of several other reports. Liberum Capital restated a “hold” rating and set a GBX 4,900 ($65.00) target price on shares of Shire PLC in a report on Thursday, August 3rd. J P Morgan Chase & Co restated an “overweight” rating on shares of Shire PLC in a report on Friday, August 4th. Credit Suisse Group restated an “outperform” rating and set a GBX 5,350 ($70.96) target price on shares of Shire PLC in a report on Tuesday, August 22nd. Barclays PLC restated an “overweight” rating and set a GBX 6,300 ($83.57) target price on shares of Shire PLC in a report on Tuesday, June 27th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Shire PLC in a report on Friday, July 7th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of GBX 5,837.29 ($77.43).
Shares of Shire PLC (SHP) opened at 3866.50 on Thursday. Shire PLC has a 1-year low of GBX 3,603.50 and a 1-year high of GBX 5,331.00. The company’s market capitalization is GBX 35.05 billion. The stock has a 50 day moving average price of GBX 3,848.68 and a 200 day moving average price of GBX 4,292.82.
In other news, insider Anne Minto purchased 190 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were bought at an average cost of GBX 3,785 ($50.21) per share, for a total transaction of £7,191.50 ($9,539.06). Also, insider Flemming Ornskov purchased 8,400 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were purchased at an average price of GBX 3,665 ($48.61) per share, for a total transaction of £307,860 ($408,356.55).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.